Telaprevir

Telaprevir is an investigational oral hepatitis C virus (HCV) protease inhibitor in phase 11 evaluation in combination with pegylated interferon and ribavirin for the treatment of chronically infected patients wit genotype 1 hepatitis C. Interim results from a phase 11 trial indicated that this drug has the potential to shorten the duration of treatment for some patients with genotype 1 HCV. Additional phase 11 trials involve the treatment of patients who have failed previous interferon-based treatment, as well as treatment in the absence of ribavirin.